Research Use Only in the United States: What the RUO Label Does and Does Not Do

"Research Use Only" is not a legal exemption. In United States federal law the phrase is a labelling statement, defined in one narrow corner of the regulations covering in vitro diagnostic products, and on its own it changes nothing about what an article legally is ^[1]. What decides the category — drug, device, diagnostic, ordinary chemical substance — is the intended use inferred from all the available evidence about the seller and the article, and the label is one item in that evidence rather than the answer to it ^[2]. A correctly applied RUO statement describes a regulatory position. It does not create one.

That distinction lands hardest on the person at the receiving dock. A carton marked "For Research Use Only" has told you what the supplier says the material is for. It has not told you that anyone reviewed the material, that the contents match the label — a question independent analyses of market-bought vials have addressed directly — or that any authority has examined either. Those are separate questions with separate answers, and the document that answers them is never the label.

Where the phrase actually comes from

The phrase has one precise home: 21 CFR 809.10(c)(2)(i). That provision exempts a product from the standard in vitro diagnostic labelling requirements when the product is in the laboratory research phase of development and is not represented as an effective in vitro diagnostic product, provided all labelling prominently bears a fixed statement ^[1]. A sibling provision at 809.10(c)(2)(ii) covers the next stage of development, the product testing phase, with its own fixed wording: "For Investigational Use Only. The performance characteristics of this product have not been established." ^[1]

For Research Use Only. Not for use in diagnostic procedures.

Two things follow that most readers miss. First, the scope is diagnostics. Part 809 governs reagents, kits and instruments used to examine specimens taken from the body; it is not a general-purpose research label for chemical substances, and it says nothing about materials of other kinds. Second, the exemption runs against a labelling rule — paragraphs (a) and (b) of 809.10 — and not against the Federal Food, Drug, and Cosmetic Act itself ^[1]. The statute continues to apply in full. A separate and much narrower registration exemption sits at 21 CFR 807.65(f), which covers establishments making devices solely for research, teaching or analysis and not introducing them into commercial distribution — a far smaller set of firms than the set that prints three words on a box ^[3].

Objective intent: the standard that decides the category

The intended-use regulations sit at 21 CFR 801.4 for devices and 21 CFR 201.128 for drugs. Both were amended by a final rule published at 86 FR 41383 on 2 August 2021 and effective 1 September 2021, which confirmed that intended use may be established from any relevant source of evidence: labelling, advertising, oral or written statements by a firm or its representatives, the circumstances surrounding distribution, and the design or composition of the article itself ^[2].

"Design or composition" is the clause that catches people out. An article built so that its only realistic application is a regulated one can be found to carry that intended use even where every printed word disclaims it. The same rule drew a line in the other direction: a firm is not treated as intending an unapproved use based solely on its knowledge that health care providers are prescribing or using the product that way ^[2]. Knowledge alone is not intent. Knowledge plus conduct that services that use is a different matter entirely, and that is the hinge the enforcement cases turn on.

What counts as inconsistent with an RUO claim

FDA's 2013 guidance, issued jointly by the device and biologics centres, sets out the conduct that puts an RUO claim in doubt: soliciting business from clinical laboratories engaged in diagnostic testing, circulating instructional or promotional labelling that carries clinical performance claims, and offering specialised technical support directed at clinical applications ^[4]. The stated concern behind the guidance is products with unproven performance characteristics reaching diagnostic use behind a disclaimer, with manufacturing controls that were never built for that purpose ^[4].

A 2024 warning letter shows the standard applied to a real firm. Following an inspection of a San Diego manufacturer in June 2023 and a review of the company's website, FDA concluded that an RUO-labelled genotyping panel was intended for clinical diagnostic use, pointing to customer testimonials describing diagnostic use and a statement from a company executive that the product formed part of a newborn screening programme ^[5]. The label said one thing. The surrounding record said another. The record decided it ^[5].

RUO is not the only regime a shipment sits inside

For substances rather than diagnostics, the nearest United States analogue is the research and development exemption under section 5(h)(3) of the Toxic Substances Control Act, implemented at 40 CFR 720.36. It reaches a new chemical substance manufactured or processed only in small quantities solely for research and development, used by or directly under the supervision of a technically qualified individual, with notice of any identified health risk given to everyone the substance reaches ^[6]. EPA states the two limits plainly: an R&D substance cannot be distributed to consumers, and the burden of proving eligibility for the exemption rests entirely with the person claiming it ^[7]. Nothing is filed and nothing is approved — the claim simply exists, available to be tested afterwards.

Hazard communication runs independently of all of this. Under 29 CFR 1910.1200 a supplier must provide a safety data sheet in a fixed sixteen-section format, with the minimum content for each section set out in Appendix D to the standard ^[8]. Laboratories then operate under 29 CFR 1910.1450, which requires that labels on incoming containers of hazardous chemicals are not removed or defaced, that safety data sheets arriving with shipments are retained and kept readily accessible to employees, and that the work is governed by a written chemical hygiene plan ^[9]. None of these duties is switched off by a research-use statement, and none of them is discharged by one.

It is worth being blunt about the questions the three words leave completely open ^[4]:

• Identity and purity of the contents — established by analysis, not by labelling, and then only as far as a mass match actually establishes identity.
• Whether any authority has reviewed the article; an RUO statement is self-applied and requires no application ^[7].
• Whether importation is lawful in the destination country, which turns on that country's own classification of the material.
• Whether hazard communication duties apply, which they do regardless ^[8].
• Whether the receiving party may pass the material on, and on what terms.

Canada takes a different route to the same question

Canadian law contains no self-applied research label of the American kind. The Food and Drugs Act defines a drug as a substance "manufactured, sold or represented for use in" the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or in restoring, correcting or modifying organic functions, and defines a device in parallel terms that expressly include an in vitro reagent ^[10]. The trigger is manufacture, sale and representation — the same intent-based test the United States applies, written into the statute rather than into a regulation about labels.

Where the American system leans on a disclaimer, the Canadian one leans on an authorisation. Part 3 of the Medical Devices Regulations governs investigational testing involving human subjects: a manufacturer or importer of a Class II, III or IV device must obtain the Minister's authorisation before selling it to a qualified investigator, and section 86 forbids importing or selling such a device unless its label carries the manufacturer's name, the device name, the bilingual statements "Investigational Device" and "Instrument de recherche", and "To Be Used by Qualified Investigators Only" ^[11]. The wording is prescribed rather than chosen, the authorisation precedes the sale, and the general prohibition on selling an unlicensed device is unaffected ^[11].

What the label does do, and what it asks of the receiving lab

Read correctly, an RUO statement is a declaration of the supplier's intended use and a boundary on the claims that supplier is willing to make. That is genuinely useful information. It tells you no performance characteristics have been established for the article, so any characterisation you need is characterisation you generate yourself. It tells you the supplier's regulatory position depends on conduct staying consistent with the wording. And it tells you which regulation the supplier believes it is standing on, which is a question worth asking directly, because the answer is often "none of them precisely".

The practical consequence is documentary. Because intended use is inferred from a whole record rather than a single line, the record a laboratory keeps is the thing that will eventually speak on its behalf. Transcribe the label statement verbatim into the receiving record rather than paraphrasing it; keep the certificate of analysis and safety data sheet filed against the lot they arrived with; leave the original container label in place, which the laboratory standard requires in any case ^[9]; and never write onto an internal label a use that the supplier's own label does not support.

• Record the statement word for word at receiving, including its punctuation, alongside the lot number and the date the container was opened.
• File the supplier's analytical documentation and safety data sheet against that lot, not against the product line, so the pairing survives a later reorder ^[8].
• Keep incoming container labels intact and legible; defacing or removing them is a separate violation of the laboratory standard ^[9].
• Treat any internal relabelling as a claim you are making, and hold it to the same standard you would hold a supplier's.

One honest caveat, and it is the most useful sentence here. Outside in vitro diagnostics and new chemical substances, no United States regulation defines "research use only" at all ^[1][6]. For most laboratory materials the phrase is a trade convention borrowed from Part 809 and applied by analogy — as is the adjacent trade term "research grade", which no regulation defines either — and its meaning is whatever the surrounding record makes of it. Any confident assertion that those three words carry a defined legal effect for a given article deserves scepticism — including, and especially, when the assertion comes from whoever is selling it.